Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma

Ito, Masaaki; Hiwasa, Takaki; Yajima, Satoshi; Suzuki, Takashi; Oshima, Yoshiteru; Nanami, Tatsuki; Sumazaki, Makoto; Shiratori, Fumiaki; Li, Shu-Yang; Iwadate, Yasuo; Sugimoto, Kazuo; Mori, Masahiro; Kuwabara, Satoshi; Takizawa, Hirotaka; Shimada, Hideaki

doi:10.1007/s10388-022-00939-0

Cited by 5 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The above results may be related to the generation of these anti-TAA autoantibodies. Similar to the results of this study, the anti-TAA autoantibodies of CFL1, EZR, CYPA have been shown certain diagnostic performance in esophageal cancer, pancreatic cancer, and breast cancer 20 – 24 . Most of the samples included in this study were serous type OC, and only 8 cases of ovarian clear cell carcinoma (OCCC) were known, and NAPSA was often abnormally high expressed in OCCC, which may be the reason for the insignificant difference in anti-TAA autoantibodies 26 , 48 .…”

Section: Discussionsupporting

confidence: 90%

“…Literature review found Cofilin 1 (CFL1), Ezrin (EZR), Cyclophilin-A (CYPA), Profilin 1 (PFN1), Napsin A (NAPSA) have been found to be associated with the development and progression of OC 15 – 19 , and are potential TAAs for ovarian cancer. Among them, the anti-TAA autoantibodies of CFL1, EZR, CYPA have been shown diagnostic potential in esophageal cancer, pancreatic cancer, and breast cancer 20 – 24 . Both CFL1 and PFN1 are actin-binding proteins, showing potential correlation function 25 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer

Cheng,

Li,

Sun

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The purpose of this study was to identify novel autoantibodies against tumor-associated antigens (TAAs) and explore a diagnostic panel for Ovarian cancer (OC). Enzyme-linked immunosorbent assay was used to detect the expression of five anti-TAA autoantibodies in the discovery (70 OC and 70 normal controls) and validation cohorts (128 OC and 128 normal controls). Machine learning methods were used to construct a diagnostic panel. Serum samples from 81 patients with benign ovarian disease were used to identify the specificity of anti-TAA autoantibodies for OC. In both the discovery and validation cohorts, the expression of anti-CFL1, anti-EZR, anti-CYPA, and anti-PFN1 was higher in patients with OC than that in normal controls. The area under the receiver operating characteristic curve, sensitivity, and specificity of the panel containing anti-CFL1, anti-EZR, and anti-CYPA were 0.762, 55.56%, and 81.31%. The panel identified 53.06%, 53.33%, and 51.11% of CA125 negative, HE4 negative and the Risk of Ovarian Malignancy Algorithm negative OC patients, respectively. The combination of the three anti-TAA autoantibodies can serve as a favorable diagnostic tool for OC and has the potential to be a complementary biomarker for CA125 and HE4 in the diagnosis of ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer

Cheng,

Li,

Sun

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…authors have previously reported that serum ACTB and CFL1 antibody titers were inversely associated with the overall survival of patients (8), suggesting the importance of actin polymerization and depolymerization in determining the prognosis. Thus, the present study aimed to evaluate the serum anti-WDR1 antibody (s-WDR1-Ab) titers in patients with various types of cancer compared with healthy donors.…”

Section: The Combination Of Positive Anti-wdr1 Antibodies With Negati...mentioning

confidence: 91%

“…Preparation and purification of antigenic WDR1 and CFL1 proteins. cDNA clones for CFL1 and WDR1 were separated using SEREX screening from the λZAP II phage cDNA library for the human esophageal carcinoma cell line, T.Tn (3,4,8), and human aortic endothelial cells (14,15), respectively. Full-length cDNAs of WDR1 were recombined into pGEX-4T-1 (Cytiva).…”

Section: Methodsmentioning

confidence: 99%

“…By sequencing the isolated cDNA clones, the SEREX method is suitable as for the large-scale screening for tumor antigens. Large-scale SEREX screening has already identified numerous antibodies or antigens, such as trophoblast cell surface antigen 2 (3), solute carrier family 2 member 1 (4), striatin 4 (5), LDL receptor related protein associated protein 1 (6), proprotein convertase subtilisin/kexin type 9 (7), cofilin 1 (CFL1) and β-actin (ACTB) (8). CFL1 can depolymerize F-actin in a pH-dependent manner and is also involved in lung, pancreatic, and gastric cancer invasion and metastasis (9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma

Ito

Yajima

Suzuki

et al. 2023

Med Int

View full text Add to dashboard Cite

WD repeat-containing protein 1 (WDR1) regulates the cofilin 1 (CFL1) activity, promotes cytoskeleton remodeling, and thus, facilitates cell migration and invasion. A previous study reported that autoantibodies against CFL1 and β-actin were useful biomarkers for diagnosing and predicting the prognosis of patients with esophageal carcinoma. Therefore, the present study aimed to evaluate the serum levels of anti-WDR1 antibodies (s-WDR1-Abs) combined with serum levels of anti-CFL1 antibodies (s-CFL1-Abs) in patients with esophageal carcinoma. Serum samples obtained from 192 patients with esophageal carcinoma and other solid cancers. And s-WDR1-Ab and s-CFL1-Ab titers were analyzed using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Compared with those of healthy donors, the s-WDR1-Ab levels were significantly higher in the 192 patients with esophageal, whereas these were not significantly higher in the samples from patients with gastric, colorectal, lung, or breast cancer. In 91 patients treated with surgery, sex, tumor depth, lymph node metastasis, stage and C-reactive protein levels were significantly associated with overall survival, as determined using the log-rank test, whereas the squamous cell carcinoma antigen, p53 antibody and s-WDR1-Ab levels tended to be associated with a worse prognosis. Although no significant difference was observed in the survival between the positive and negative groups of s-WDR1-Abs or s-CFL1-Abs alone in the Kaplan-Meier test, the patients in the s-WDR1-Ab-positive and s-CFL1-Ab-negative groups exhibited a significantly poorer prognosis in the overall survival analysis. On the whole, the present study demonstrates that the combination of positive anti-WDR1 antibodies with negative anti-CFL1 antibodies in serum may be a poor prognostic factor for patients with esophageal carcinoma.

show abstract

Identification of two hub genes and miRNA‑mRNA interactions in chronic obstructive pulmonary disease (COPD) plasma

Qian,

Li,

et al. 2024

Journal of Asthma

View full text Add to dashboard Cite

Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma

Cited by 5 publications

References 40 publications

Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer

Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer

The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma

Identification of two hub genes and miRNA‑mRNA interactions in chronic obstructive pulmonary disease (COPD) plasma

Contact Info

Product

Resources

About